BioWorld

Oct. 12, 2009

Me-Too Drugs Not Dead Yet, but No Exceptions on Value

At last month's BioPharm America conference in San Francisco, biotech experts brushed aside the once-popular business model of using drug delivery or reformulation to provide incremental improvements to existing drugs. Read More

Money Raised Year to Date

When Biotechs Hit Hard Times, Leases Can Be the Last Straw

Money Raised By Biotech in 2009

Week in Review

Word on the Street

Week in Washington

FDA Approvals in September

Phase I Clinical Trials Update: September 2009

Phase II Clinical Trials Update: September 2009

Pivotal/Phase III Clinical Trials Update: September 2009

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Non-U.S. Clinical Trials And Regulatory Actions: September 2009

FDA Submissions, Approvals And Other Actions: September 2009

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...